Physician profile
David Stuart Eilender
NPI 1700823705
$18,521.89
in general payments reported to CMS, 2019-2025
68 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,973 · 2020: $6,293 · 2021: $4,079 · 2022: $502 · 2023: $181 · 2024: $150 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578 · Education: $97.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $577.81 |
| Education | $97.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $3,401.29 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $2,300.00 | 2021 | |
| Karyopharm Therapeutics INC. | $1,704.61 | 2020-2021 | |
| Immunomedics, INC. | $1,362.59 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $1,136.75 | 2019-2024 | Lynparza |
| Celgene Corporation | $756.86 | 2019-2021 | |
| Amgen INC. | $702.06 | 2019-2023 | |
| Janssen Biotech, INC. | $701.82 | 2019-2025 | Rybrevant |
| Genentech USA, INC. | $552.28 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $330.23 | 2019-2021 | |
| Incyte Corporation | $329.73 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $315.99 | 2019-2023 | Abilify |
| Alexion Pharmaceuticals, INC. | $305.11 | 2019-2022 | |
| Beigene USA, INC. | $293.38 | 2020-2023 | Brukinsa |
| Eisai INC. | $292.53 | 2019-2021 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Eilender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.